DThe gigantic Dow Chemical-DuPont merger is experiencing some serious antitrust pushback in Europe and some Washington insiders feel it could get blocked, The Post has learned.
The two companies met last week with European Union regulators to detail their views as to why the deal should get approved.
A similar effort last year failed to resolve EU concerns. A decision is expected next month.
“I wouldn’t be surprised if it got blocked,” said one Washington source close to the situation, but not working on the deal, while a source close to the parties said he was “cautiously optimistic.”
A merger of Dow, with a $65 billion market cap, and DuPont, worth $64 billion, would create a new entity called DowDuPont, the world’s largest chemical company.
If the companies offer concessions — like selling of assets — they would need to do so by late January, the source said.
The biggest concern of the EU is that the new entity will spend less on crop-protection research and thus reduce global yields, sources said.
The merger, which will reorder and concentrate power in the biotech seed industry, has been the subject of intense scrutiny in the US, as well. At least 10 states and the Justice Department are weighing the deal.
Full Content: New York Post
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
House Budget Bill’s Moratorium on State AI Laws Could Undo A Range of Tech Regs, Critics Say
May 14, 2025 by
CPI
Microsoft Nears EU Antitrust Resolution Over Teams Bundling, Sources Say
May 14, 2025 by
CPI
CMA Investigates Aviva’s £3.6B Acquisition of Direct Line Group
May 14, 2025 by
CPI
Google Urges Texas Judge to Disregard Virginia Antitrust Ruling
May 14, 2025 by
CPI
Anthropic Ordered to Respond After AI Allegedly Fabricates Citation in Legal Filing
May 14, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Healthcare Antitrust
May 14, 2025 by
CPI
Healthcare & Antitrust: What to Expect in the New Trump Administration
May 14, 2025 by
Nana Wilberforce, John W O'Toole & Sarah Pugh
Patent Gaming and Disparagement: Commission Fines Teva For Improperly Protecting Its Blockbuster Medicine
May 14, 2025 by
Blaž Višnar, Boris Andrejaš, Apostolos Baltzopoulos, Rieke Kaup, Laura Nistor & Gianluca Vassallo
Strategic Alliances in the Pharma Sector: An EU Competition Law Perspective
May 14, 2025 by
Christian Ritz & Benedikt Weiss
Monopsony Power in the Hospital Labor Market
May 14, 2025 by
Kevin E. Pflum & Christian Salas